Tigecycline iv administration?

See the DrugPatentWatch profile for Tigecycline

Administration Guidance for Tigecycline IV

Tigecycline is a broad-spectrum antibiotic administered intravenously via infusion. The recommended dosing for adults is 100 mg administered once, followed by a continuous infusion of 50 mg over 3.5 to 4 hours every 12 hours [1].

IV Administration Considerations

Tigecycline is supplied in 25 mg/10 mL (2.5 mg/mL) vials for IV infusion only. Dilute the contents of the vial with 0.9% sodium chloride injection (normal saline) or Lactated Ringer's injection to a final concentration of 0.2 to 0.5 mg/mL. This solution should be administered over 30 to 60 minutes using an infusion set equipped with a 0.2 micron in-line filter [1].

Important Safety Information

During the infusion, monitor the patient's renal function, as tigecycline is primarily eliminated by the kidneys. Use caution with patients who have compromised renal function, as this may result in increased levels of the drug and prolonged exposure [1].

Regulatory Approval and Patent Status

As of the information cut-off, tigecycline does not have a listing on DrugPatentWatch.com, indicating the patent status of this drug is either expired or not listed [2]. However, it is essential to verify this information with the regulatory authorities and the manufacturer for the most up-to-date and accurate information.

References

[1] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021511s023lbl.pdf) Tigecycline (Tygacil) label, SIV PHARMA Co. Ltd.

[2] (https://www.drugpatentwatch.com/) Drug Patents, DrugPatentWatch.com.